GBM Clinical Trial - Integrative Analysis of Human Glioblastoma Multiforme

Status Recruiting

Clinical Trial Summary

Integrative analysis of GBM

Clinical Trial Description

The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses. ;

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03005132
Study type	Observational
Source	Shanghai 10th People's Hospital
Contact	Da Fu, PhD
Phone	00-86-21-66301604
Email	fu800da900@126.com
Status	Recruiting
Phase	N/A
Start date	January 2016
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06147505` - Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)	Phase 1/Phase 2
Recruiting	`NCT05076513` - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	Early Phase 1
Recruiting	`NCT04528680` - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma	Phase 1/Phase 2
Terminated	`NCT03149575` - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM	Phase 3
Completed	`NCT01478178` - Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma	Phase 1/Phase 2
Terminated	`NCT03119064` - BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT05686798` - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.	Phase 1
Recruiting	`NCT03758014` - Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients	Phase 2/Phase 3
Terminated	`NCT01205334` - Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme	Phase 1/Phase 2
Active, not recruiting	`NCT00114309` - 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma	Phase 2
Not yet recruiting	`NCT03746288` - To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)	Phase 2
Recruiting	`NCT04681677` - Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab	Phase 2
Completed	`NCT01856933` - BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)	Phase 2
Terminated	`NCT04763031` - Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT	N/A
Completed	`NCT00107003` - GW572016 to Treat Recurrent Malignant Brain Tumors	Phase 2
Completed	`NCT03426891` - Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma	Phase 1
Recruiting	`NCT06092255` - A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.	N/A
Recruiting	`NCT04115761` - Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients	Phase 2
Recruiting	`NCT05954858` - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma	N/A
Recruiting	`NCT02861898` - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma	Phase 1/Phase 2